Aadi Bioscience, Inc.
Index- P/E- EPS (ttm)-11.45 Insider Own13.54% Shs Outstand20.97M Perf Week0.69%
Market Cap276.95M Forward P/E- EPS next Y-2.78 Insider Trans-0.12% Shs Float18.17M Perf Month-8.09%
Income-135.20M PEG- EPS next Q-0.74 Inst Own64.80% Short Float3.52% Perf Quarter-13.33%
Sales6.70M P/S41.34 EPS this Y-712.40% Inst Trans4.70% Short Ratio4.19 Perf Half Y-26.82%
Book/sh5.18 P/B2.52 EPS next Y7.60% ROA-90.50% Target Price43.50 Perf Year-50.64%
Cash/sh5.60 P/C2.33 EPS next 5Y- ROE-103.90% 52W Range11.00 - 32.99 Perf YTD-45.88%
Dividend- P/FCF- EPS past 5Y-1.30% ROI-77.90% 52W High-60.32% Beta1.45
Dividend %- Quick Ratio9.80 Sales past 5Y- Gross Margin92.30% 52W Low19.00% ATR0.63
Employees67 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)46.45 Volatility3.36% 5.01%
OptionableYes Debt/Eq0.00 EPS Q/Q10.50% Profit Margin- Rel Volume0.30 Prev Close13.07
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume152.89K Price13.09
Recom1.60 SMA20-2.16% SMA50-0.83% SMA200-23.25% Volume8,166 Change0.15%
Jan-11-22Initiated Jefferies Buy $45
Oct-01-21Initiated Cowen Outperform
Sep-14-21Initiated Ladenburg Thalmann Buy $51
Sep-08-21Initiated Piper Sandler Overweight $45
Sep-01-22 08:00AM  
Aug-10-22 08:00AM  
Aug-04-22 06:21AM  
Jul-28-22 08:30AM  
Jun-23-22 08:00AM  
Jun-01-22 08:00AM  
May-31-22 08:00AM  
May-26-22 05:10PM  
May-18-22 07:00AM  
May-12-22 08:32AM  
May-09-22 08:00AM  
May-04-22 08:00AM  
Apr-28-22 05:07PM  
Apr-18-22 08:00AM  
Apr-08-22 01:09PM  
Apr-01-22 05:13AM  
Mar-31-22 02:45PM  
Mar-17-22 07:00AM  
Mar-01-22 07:00AM  
Feb-25-22 04:41AM  
Feb-23-22 07:00AM  
Jan-04-22 04:30PM  
Dec-28-21 09:38AM  
Dec-23-21 12:38PM  
Dec-21-21 09:38AM  
Dec-16-21 09:38AM  
Dec-08-21 09:38AM  
Nov-27-21 06:01AM  
Nov-23-21 04:22PM  
Nov-15-21 08:00AM  
Nov-13-21 01:35PM  
Nov-10-21 07:00AM  
Nov-09-21 08:00AM  
Nov-01-21 04:05PM  
Oct-25-21 08:00AM  
Oct-22-21 08:00AM  
Oct-19-21 05:22PM  
Oct-06-21 08:00AM  
Sep-20-21 08:30AM  
Sep-13-21 08:00AM  
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Desai NeilSee RemarksMar 18Sale20.073,55071,2341,915,543Mar 22 05:34 PM